Efsevia Albanis MD
Assistant Clinical Professor, Medicine - Liver Diseases, Icahn School of Medicine at Mount Sinai
Join to View Full Profile
434 West 33rd Street, Suite 1102Neurogene, Inc.New York, NY 10011
Phone+1 609-216-4530
Dr. Albanis is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
Icahn School of Medicine at Mount Sinai/St Luke’s-Roosevelt Hospital CenterFellowship, Gastroenterology, 1997 - 2000- Icahn School of Medicine at Mount Sinai/Mount Sinai HospitalResidency, Internal Medicine, 1994 - 1997
- Icahn School of Medicine at Mount SinaiClass of 1994
Certifications & Licensure
NY State Medical License 1996 - 2025
Publications & Presentations
PubMed
- 228 citationsSofosbuvir with pegylated interferon alfa-2a and ribavirin for treatment-naive patients with hepatitis C genotype-1 infection (ATOMIC): An open-label, randomised, mult...Kris V. Kowdley, Eric Lawitz, Israel Crespo, Tarek Hassanein, M. Davis
Lancet. 2013-06-15 - 244 citationsSofosbuvir in combination with peginterferon alfa-2a and ribavirin for non-cirrhotic, treatment-naive patients with genotypes 1, 2, and 3 hepatitis C infection: a rand...Eric Lawitz, J. Lalezari, Tarek Hassanein, Kris V. Kowdley, Fred Poordad
The Lancet. Infectious Diseases. 2013-05-01 - 85 citationsSofosbuvir (GS-7977) plus peginterferon/ribavirin in treatment-naïve patients with HCV genotype 1: a randomized, 28-day, dose-ranging trial.Maribel Rodriguez-Torres, Eric Lawitz, Kris V. Kowdley, David R. Nelson, E. DeJesus
Journal of Hepatology. 2013-04-01
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
